Evidence map›Paper›PMID 26157116›Full record

ArticleJournal of virology2015

Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.

Joshua D Amos, Jonathon E Himes, Lawrence Armand, Thaddeus C Gurley, David R Martinez, Lisa Colvin, Krista Beck, R Glenn Overman, Hua-Xin Liao, M Anthony Moody and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Joshua D AmosDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Jonathon E HimesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Lawrence ArmandDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Thaddeus C GurleyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
David R MartinezDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Lisa ColvinDivision of Laboratory Animal Resources, Duke University Medical Center, Durham, North Carolina, USA.
Krista BeckDivision of Laboratory Animal Resources, Duke University Medical Center, Durham, North Carolina, USA.
R Glenn OvermanDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA sallie.permar@duke.edu.
Duke Medical Center · USDuke University · USDuke University Hospital · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI HARRISON, STEPHEN COPLAN · 2006 to 2011
$290.5M
Antibody protection against SIV transmissionR21AI100760 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2012 to 2013
$432k
NIAID NIH HHS R21 AI100760NIAID NIH HHS R21AI100760NIAID NIH HHS U19 AI067854
6 · The paper itself

Abstract

unlabelledThe initial phases of acute human immunodeficiency virus type 1 (HIV-1) infection may be critical for development of effective envelope (Env)-specific antibodies capable of impeding the establishment of the latent pool of HIV-1-infected CD4(+) T cells, preventing virus-induced immune hyperactivation to limit disease progression and blocking vertical virus transmission. However, the initial systemic HIV-1 Env-specific antibody response targets gp41 epitopes and fails to control acute-phase viremia. African-origin, natural simian immunodeficiency virus (SIV) hosts do not typically progress to AIDS and rarely postnatally transmit virus to their infants, despite high milk viral loads. Conversely, SIV-infected rhesus macaques (RMs), Asian-origin nonnatural SIV hosts, sustain pathogenic SIV infections and exhibit higher rates of postnatal virus transmission. In this study, of acute SIV infection, we compared the initial systemic Env-specific B cell responses of AGMs and RMs in order to probe potential factors influencing the lack of disease progression observed in AGMs. AGMs developed higher-magnitude plasma gp120-specific IgA and IgG responses than RMs, whereas RMs developed more robust gp140-directed IgG responses. These gp120-focused antibody responses were accompanied by rapid autologous neutralizing responses during acute SIV infection in AGMs compared to RMs. Moreover, acute SIV infection elicited a higher number of circulating Env-specific memory B cells in peripheral blood of AGMs than in the blood of RMs. These findings indicate that AGMs have initial systemic Env-specific B cell responses to SIV infection distinct from those of a nonnatural SIV host, resulting in more functional SIV-specific humoral responses, which may be involved in impairing pathogenic disease progression and minimizing postnatal transmission. IMPORTANCE: Due to the worldwide prevalence of HIV-1 infections, development of a vaccine to prevent infection or limit the viral reservoir remains an important goal. HIV-1-infected humans, as well as SIV-infected nonnatural SIV hosts, develop pathogenic infections and readily transmit the virus to their infants. Conversely, natural SIV hosts do not develop pathogenic infections and rarely transmit the virus to their infants. The immunologic factors contributing to these favorable outcomes in natural SIV hosts could prove invaluable for directing HIV-1 vaccine and therapy design. This study identified distinctions in the specificity and function of the initial systemic SIV envelope-specific B cell response that developed during acute SIV infection in natural and nonnatural SIV host species. Identification of distinct acute B cell responses in natural SIV hosts may inform vaccine strategies seeking to elicit similar responses prior to or during the initial phases of acute HIV-1 infection.

Indexed as

Acute DiseaseAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesChlorocebus aethiopsFemaleHumansImmunoglobulin GImmunologic MemoryMacaca mulattaMembrane GlycoproteinsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral Envelope ProteinsAntibodies, NeutralizingAntibodies, Viralgp120 protein, Simian immunodeficiency virusImmunoglobulin GMembrane GlycoproteinsViral Envelope Proteins

Identifiers

PMID26157116
PMCPMC4542363
OpenAlexW1820045625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.